Drug Profile


Alternative Names: FVH-1; FVH1 (DNA-based influenza vaccine) - Inovio; Influenza H1N1 seasonal influenza vaccine - Inovio; INO 3605; INO 3609; SynCon® H1HA consensus DNA vaccine - Inovio; SynCon® universal H1N1 influenza vaccine - Inovio

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Pennsylvania
  • Developer Inovio Pharmaceuticals
  • Class Influenza A virus H1N1 vaccines; Influenza virus DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(In the elderly, Prevention, In volunteers) in Canada (Intradermal, Injection)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H1N1-subtype(Prevention, In volunteers) in USA (Intradermal, Injection)
  • 01 Mar 2015 Inovio Pharmaceuticals and University of Manitoba complete enrolment in its Phase-I trial for Influenza-A virus H1N1 subtype (prevention in elderly volunteers) in Canada (NCT01587131)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top